$104 Million

Natera

Follow-on Offering

Bookrunner, July 2018

Natera
Natera is a diagnostics company that has non-invasive tests to evaluate risk, and thereby enable early-detection of prenatal and oncology conditions. The use of blood-based diagnostic tests requires the measurement of very small amounts of relevant genetic material circulating within a much larger blood sample. Natera’s approach combines proprietary molecular biology and computational techniques to measure genomic variations in tiny amounts of DNA, as small as a single cell